Clinical Trial

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-23.
Trial Details
NCT Number NCT07046221
Lead Sponsor Fujian Cancer Hospital
Conditions Esophagus Cancer
Enrollment 60 participants
Start Date 2025-08-01
Primary Completion 2027-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-20